Unraveling the Pharmacognostic and Mechanistic Landscape of Bombax ceiba L.: Exploring its Phytoconstituents and Therapeutic Potentials
Open Access
- 30 June 2026
- journal article
- Published by Informatics Publishing Limited in Journal of Natural Remedies
- p. 1593-1608
Abstract
Background: Bombax ceiba (B. ceiba) L. is an important plant in the Malvaceae family, widely distributed across tropical and subtropical areas of Africa, Asia and Australia. The medicinal properties of the plant are highly valued under various forms of traditional medicines such as Ayurveda, Siddha, Unani, and others. It has been used to treat gastrointestinal, skin, urinary, and wound-healing ailments for a long time. The experimental literature is increasingly becoming popular, but a focused integration linking pharmacognostic identity to mechanistic pharmacology is largely missing. Aim: The objective of the mini-review is to combine classical pharmacognosy with molecular pharmacology of B. ceiba. As a future orientation in drug development, the morphological authentication, phytochemical characterisation and diversity and the experimentally deciphered bioactivities together with the impact of innovative nano-formulation may be brought into a unified document defined in a “bench-to-biological-pathway”. Methods: The pharmacognostic characterisation, herbal medicine and ethnopharmacology, phytochemistry, and pharmacology of species belonging to the genus Bombax, specifically B. ceiba, were systematically reviewed. This allowed us to assess its medical utility and market potential in the context of a rapidly evolving functional food industry. Relevant information was included in an operational model of pharmacognosy phytochemistry mechanism. Result: Stigmasterol, β-amyrin palmitate, lupeol palmitate, and malvalic acid are compounds purified from the parts of B. ceiba. The plant is abundantly loaded with lupeol, mangiferin, β-sitosterol, quercetin and its derivatives, shamimin, anthocyanins, naphthoquinones, and others and also possesses a vast scope of applications in cosmetics, pharmacy, and food industry. Conclusion: B. ceiba emerges as a good multi-target ethnomedicine; it has pharmacognostic identity and good pharmacological preclinical evidence. According to findings, there is a correlation between conventional uses and modulation of the NF-κB, Nrf2, MAPK, and AMPK pathways Consequently, it seems likely a good candidate for phytopharmaceutical preparation. In future perspective, it is important to establish protocols for extracting the plant, study pharmacokinetic, and implement controlled clinical trials to transform this wealth into evidence-based and easily perceptible therapeutic agents. Major Findings: B. ceiba L. covers key bioactives — lupeol, mangiferin, β-sitosterol, and quercetin derivatives — that modulate NF-κB, Nrf2, MAPK, and AMPK pathways, granting anti-inflammatory, antioxidant, hepatoprotective, and antidiabetic activities, though the absence of controlled clinical trials and standardised extracts remains a critical translational gap demanding systematic pharmacokinetic and clinical validation.Keywords
This publication has 83 references indexed in Scilit:
- Exploring the Therapeutic Potential of Bombax ceiba L. Flowers as Source of Functional Food Development: A ReviewChemistry & Biodiversity, 2025
- Comparative phytochemical, antioxidant and antifungal evaluation of successive extracts of Bombax ceiba L. thornsDiscover Plants, 2024
- Using Small Branches of Bombax ceiba Instead of Stem Bark for a Conservative Sourcing Approach: Comparative Studies of Chemical Profiling by LC‐MS, GC‐MS, and HPLCChemistrySelect, 2023
- Bombax ceiba flower extract mediated synthesis of Se nanoparticles for antibacterial activity and urea detectionWorld Journal of Microbiology and Biotechnology, 2023
- Nanoformulation of Plant-Based Natural Products for Type 2 Diabetes Mellitus: From Formulation Design to Therapeutic ApplicationsCurrent Therapeutic Research, 2022
- Berberine as a natural modulator of inflammatory signaling pathways in the immune system: Focus on NF‐κB, JAK/STAT, and MAPK signaling pathwaysPhytotherapy Research, 2022
- Current hurdles to the translation of nanomedicines from bench to the clinicDrug Delivery and Translational Research, 2021
- The apatinib inhibits breast cancer cell line MDA-MB-231 in vitro by inducing apoptosis, cell cycle arrest, and regulating nuclear factor-κB (NF-κB) and mitogen-activated protein kinase (MAPK) signaling pathwaysBreast Cancer, 2020
- Bioassay-guided studies on Bombax ceiba leaf extract: isolation of shamimoside, a new antioxidant xanthone C-glucosideChemistry of Natural Compounds, 2012
- Pharmacology of Bombax ceiba Linn.2012